Amegakaryocytic Thrombocytopenia

Overview

4.1 out of 5 (8 Reviews)

Credits

1.00

Post Assessment Questions

5

Start Date

1 Sep 2023

Last Review Date

1 May 2024

Expiration Date

31 Aug 2026

Estimated Time To Finish

60 Minutes


 
Need Help?  If you have a system or content concerns, please contact support@statpearls.com

Activity Description

Amegakaryocytic thrombocytopenia is a severe form of thrombocytopenia characterized by diminished or absent megakaryocytes in the bone marrow without other abnormalities. This condition manifests in both congenital and acquired forms. Congenital amegakaryocytic thrombocytopenia manifests with severe thrombocytopenia and bleeding issues at birth, often progressing to bone marrow failure, whereas acquired amegakaryocytic thrombocytopenia typically emerges later in life and may be linked to immune-mediated mechanisms.

Diagnosis involves bone marrow biopsy and genetic testing. Clinicians diagnose congenital amegakaryocytic thrombocytopenia by assessing characteristic bone marrow features and confirming variations in the c-MPL gene. At the same time, diagnosing acquired amegakaryocytic thrombocytopenia relies on clinical suspicion and bone marrow examination showing reduced or absent megakaryocytes.

Treatment approaches differ between the 2 forms. Allogeneic hematopoietic stem cell transplant is the sole curative option for the congenital form associated with a c-MPL mutation. At the same time, treating the acquired form involves addressing the underlying cause, often in conjunction with immunosuppressive medications or bone marrow transplantation. Management requires a comprehensive, multidisciplinary approach tailored to individual patient needs, focusing on bleeding manifestations and preventing progression to bone marrow failure. This topic discusses the etiology, pathophysiology, evaluation, and management of amegakaryocytic thrombocytopenia, providing healthcare professionals with the necessary knowledge to reduce overall morbidity and mortality associated with amegakaryocytic thrombocytopenia.


UAN: JA4008338-0000-23-6087-H01-P

Target Audience

This activity has been designed to meet the educational needs of physicians, physician associates, nurses, pharmacists, and nurse practitioners.

Learning Objectives

At the conclusion of this activity, the learner will be better able to:

  • Differentiate between congenital and acquired forms of amegakaryocytic thrombocytopenia based on clinical presentation and diagnostic criteria.

  • Implement appropriate diagnostic tests, including bone marrow biopsy and genetic testing, for suspected cases of amegakaryocytic thrombocytopenia.

  • Apply evidence-based treatment strategies, including allogeneic hematopoietic stem cell transplant and immunosuppressive therapy, to manage amegakaryocytic thrombocytopenia.

  • Collaborate with hematology clinicians, geneticists, and other healthcare professionals to ensure comprehensive care for patients with amegakaryocytic thrombocytopenia.

Pharmacy Activity Type:
Disease/Drug Therapy Related


Disclosures

StatPearls, LLC requires everyone who influences the content of an educational activity to disclose relevant financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All relevant conflict(s) of interest have been mitigated. Hover over contributor names for financial disclosures. Others involved in planning this educational activity have no relevant financial relationships to disclose.

Commercial Support: This activity has received NO commercial support.

Continuing Education Accreditation Information

In support of improving patient care, StatPearls, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Pharmacists: StatPearls, LLC designates this activity for a maximum of 1.00 ACPE credit(s). (UAN: JA4008338-0000-23-6087-H01-P ). Pharmacists should only claim credit commensurate with the extent of their participation in the activity.

Please consult your professional licensing board for information on the applicability and acceptance of continuing education credit for this activity.

Method of Participation and Credit

  1. Register for the activity.    
  2. Review the target audience, learning objectives, and disclosure information.
  3. Study the educational content of the enduring material.
  4. Choose the best answer to each activity test question. To receive credit and a certificate, you must pass the test questions with a minimum score of 100%.
  5. Complete the post-activity assessment survey.

If you have concerns regarding the CE/CME system, please contact support@statpearls.com.

Disclaimer

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Faculty may discuss investigational products or off-label uses of products regulated by the FDA. Readers should verify all information before employing any therapies described in this educational activity.

The information provided for this activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition. The information presented does not necessarily reflect the views of StatPearls or any commercial supporters of educational activities on statpearls.com. StatPearls expressly disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through a participant's misunderstanding of the content.

Unapproved Uses of Drugs/Devices: In accordance with FDA requirements, the audience is advised that information presented in this continuing education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA-approved package insert for each drug/device for full prescribing/utilization information.

Cancellation Policy: Please see the cancellation policy. StatPearls, LLC reserves the right to cancel any course due to unforeseen circumstances.

 

 
 

Reviews

Elizabeth E. on 6/20/2022

NISHA N. on 11/17/2022

Dr Sruthi G. on 8/3/2023

Swaminathan I. on 8/22/2023

Richard C. on 10/10/2023

louis v. on 11/3/2023

Tamara H. on 1/23/2024

douglas t. on 3/13/2024

Unlimited Pharmacist CE

Stay up to date on the latest medical knowledge with 6673 CE activities. In these online self-assessment activities, read our reference articles and test your knowledge with more than 7924.5 hours of CE.

Single Activity

Take this single activity

$29 1 activity

6 Month Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$119 per half year per user

1 Year Unlimited Pharmacist CE

Access to all the Unlimited Pharmacist CE activities in all specialties.

$199 per 1 year per user